Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 18, 2025
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
GlobeNewswire
·
March 18, 2025
-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical …
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
GlobeNewswire
·
March 18, 2025
SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, …
NeuroOne CEO Joins Today’s Marketplace To Discuss The Latest Treatments for Epilepsy
GlobeNewswire
·
March 18, 2025
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) CEO Dave Rosa and Jessica Clark, DNP, RN, Dean of the College of Nursing at …
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
GlobeNewswire
·
March 18, 2025
HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”) and Alvotech (NASDAQ: ALVO …
AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test
GlobeNewswire
·
March 18, 2025
AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026 LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to …
New InStride Health Data Reveals Overall Clinical Improvement in 98% of Youth with Anxiety and/or OCD
GlobeNewswire
·
March 18, 2025
BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- InStride Health, an outpatient provider of specialty pediatric anxiety and Obsessive-Compulsive Disorder (OCD) treatment, today announced new data reflecting clinically meaningful results of its program’s impact …
Prenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market
GlobeNewswire
·
March 18, 2025
Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) -- IM8, the premium supplements brand co-founded by David Beckham, …
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
GlobeNewswire
·
March 18, 2025
HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, …
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
GlobeNewswire
·
March 18, 2025
Ramat Gan, Israel, March 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today …
Omega Laboratories Reports Completion of Method Validation with Cannabix Technologies Inc. for Marijuana Breath Detection
GlobeNewswire
·
March 18, 2025
VANCOUVER, British Columbia, March 18, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports the following news release was issued by Omega Laboratories, Inc. today. MOGADORE, …
Cytrellis Secures Health Canada and Saudi Food and Drug Authority Approval for ellacor® with Micro-Coring® Technology
GlobeNewswire
·
March 18, 2025
WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Cytrellis Biosystems, a medical technology company specializing in novel aesthetic solutions, today announces that it has received approval from Health Canada and the Saudi Food and Drug Authority (SFDA) to …
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
GlobeNewswire
·
March 18, 2025
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in …
New Report Highlights 100+ Actionable Strategies for Climate-Resilient Water and Sanitation in Frontline Communities Across US
GlobeNewswire
·
March 18, 2025
Oakland, CA, USA, March 18, 2025 (GLOBE NEWSWIRE) -- New research released today by the Pacific Institute and DigDeep outlines over 100 actionable strategies for frontline communities’ water and sanitation systems in the face of intensifying climate …
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
GlobeNewswire
·
March 18, 2025
OCU200 has a very favorable safety and tolerability profile No serious adverse events related to the study drug have been reported Dosing of the second cohort has been approved MALVERN, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the …
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
GlobeNewswire
·
March 18, 2025
NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025
GlobeNewswire
·
March 18, 2025
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the …
Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025
GlobeNewswire
·
March 18, 2025
CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) …
IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025
GlobeNewswire
·
March 18, 2025
– Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines – NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, has been named …
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
GlobeNewswire
·
March 18, 2025
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced to a new …
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
GlobeNewswire
·
March 18, 2025
GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted for delivery in 2025 associated with its medical countermeasures …